Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Metformin | 9 | 2025 | 132 | 3.580 |
Why?
|
| Ovarian Neoplasms | 19 | 2025 | 787 | 3.560 |
Why?
|
| Culturally Competent Care | 2 | 2017 | 13 | 1.110 |
Why?
|
| Hypoglycemic Agents | 5 | 2019 | 361 | 0.960 |
Why?
|
| Sexual and Gender Minorities | 2 | 2017 | 230 | 0.850 |
Why?
|
| Gynecology | 2 | 2023 | 129 | 0.670 |
Why?
|
| Obstetrics | 2 | 2023 | 123 | 0.670 |
Why?
|
| BRCA1 Protein | 2 | 2018 | 207 | 0.610 |
Why?
|
| Glycolysis | 2 | 2017 | 184 | 0.600 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 80 | 0.590 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2016 | 55 | 0.590 |
Why?
|
| Maternal Health Services | 1 | 2017 | 16 | 0.560 |
Why?
|
| Homosexuality, Female | 1 | 2017 | 16 | 0.560 |
Why?
|
| Marriage | 1 | 2017 | 25 | 0.560 |
Why?
|
| Fertilization in Vitro | 1 | 2017 | 58 | 0.550 |
Why?
|
| Spouses | 1 | 2017 | 31 | 0.550 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 76 | 0.500 |
Why?
|
| Carcinosarcoma | 1 | 2016 | 24 | 0.490 |
Why?
|
| Tumor Microenvironment | 3 | 2019 | 521 | 0.480 |
Why?
|
| Epithelial Cells | 2 | 2017 | 702 | 0.480 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2016 | 59 | 0.480 |
Why?
|
| Parents | 1 | 2017 | 295 | 0.450 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 2555 | 0.450 |
Why?
|
| Hyperglycemia | 1 | 2015 | 176 | 0.440 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 92 | 0.430 |
Why?
|
| Cell Line, Tumor | 10 | 2020 | 2662 | 0.420 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2015 | 1308 | 0.410 |
Why?
|
| Genital Neoplasms, Female | 1 | 2014 | 110 | 0.410 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 212 | 0.400 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 437 | 0.400 |
Why?
|
| Female | 25 | 2025 | 47901 | 0.400 |
Why?
|
| Paclitaxel | 1 | 2014 | 495 | 0.390 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 2366 | 0.390 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 462 | 0.390 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2011 | 34 | 0.370 |
Why?
|
| Estradiol | 1 | 2011 | 250 | 0.340 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 391 | 0.340 |
Why?
|
| Adipocytes | 3 | 2020 | 170 | 0.320 |
Why?
|
| Indoles | 1 | 2011 | 305 | 0.320 |
Why?
|
| Contraceptives, Oral, Synthetic | 1 | 2009 | 6 | 0.320 |
Why?
|
| Norethindrone | 1 | 2009 | 12 | 0.320 |
Why?
|
| Ethinyl Estradiol | 1 | 2009 | 16 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1398 | 0.310 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2009 | 105 | 0.300 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2019 | 167 | 0.290 |
Why?
|
| Mice | 12 | 2020 | 12133 | 0.280 |
Why?
|
| Vacuum Curettage | 1 | 2007 | 5 | 0.280 |
Why?
|
| Models, Biological | 1 | 2015 | 1785 | 0.280 |
Why?
|
| Humans | 27 | 2025 | 92352 | 0.280 |
Why?
|
| Tramadol | 1 | 2007 | 14 | 0.280 |
Why?
|
| Ibuprofen | 1 | 2007 | 29 | 0.280 |
Why?
|
| Policy Making | 2 | 2017 | 62 | 0.270 |
Why?
|
| Neoplasm Staging | 3 | 2025 | 2032 | 0.270 |
Why?
|
| Disease Models, Animal | 3 | 2011 | 2450 | 0.260 |
Why?
|
| Neoplasms | 4 | 2021 | 3123 | 0.260 |
Why?
|
| Health Policy | 2 | 2017 | 190 | 0.240 |
Why?
|
| Pain | 1 | 2007 | 406 | 0.230 |
Why?
|
| Signal Transduction | 2 | 2015 | 3505 | 0.230 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2025 | 85 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 5 | 2014 | 569 | 0.210 |
Why?
|
| Mice, Nude | 4 | 2020 | 825 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1211 | 0.200 |
Why?
|
| Animals | 13 | 2020 | 28059 | 0.200 |
Why?
|
| Cell Proliferation | 5 | 2020 | 1720 | 0.200 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 1072 | 0.190 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2020 | 25 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 1 | 2025 | 400 | 0.180 |
Why?
|
| Faculty, Medical | 1 | 2023 | 198 | 0.180 |
Why?
|
| Double-Blind Method | 1 | 2025 | 1755 | 0.170 |
Why?
|
| Blotting, Western | 2 | 2014 | 793 | 0.170 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 1178 | 0.170 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2021 | 168 | 0.160 |
Why?
|
| Tumor Burden | 3 | 2020 | 314 | 0.160 |
Why?
|
| Telephone | 1 | 2019 | 36 | 0.160 |
Why?
|
| Retinal Dehydrogenase | 1 | 2019 | 7 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 621 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 501 | 0.150 |
Why?
|
| Stromal Cells | 1 | 2019 | 147 | 0.150 |
Why?
|
| Genetic Counseling | 1 | 2019 | 101 | 0.150 |
Why?
|
| Pregnancy | 3 | 2021 | 3113 | 0.150 |
Why?
|
| Sphingosine | 1 | 2019 | 74 | 0.150 |
Why?
|
| Lysophospholipids | 1 | 2019 | 66 | 0.150 |
Why?
|
| Carcinogenesis | 1 | 2019 | 223 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 167 | 0.140 |
Why?
|
| Cell Survival | 2 | 2020 | 1006 | 0.130 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 189 | 0.130 |
Why?
|
| Apoptosis | 3 | 2014 | 1737 | 0.130 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 35 | 0.130 |
Why?
|
| Fallopian Tubes | 1 | 2017 | 46 | 0.130 |
Why?
|
| Aged | 3 | 2025 | 19953 | 0.130 |
Why?
|
| Internet | 1 | 2019 | 331 | 0.130 |
Why?
|
| Chemoprevention | 1 | 2017 | 93 | 0.130 |
Why?
|
| Omentum | 2 | 2020 | 74 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 291 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 3 | 2019 | 1045 | 0.130 |
Why?
|
| Carbon | 1 | 2016 | 96 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 651 | 0.120 |
Why?
|
| Phenformin | 1 | 2015 | 5 | 0.120 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2015 | 13 | 0.120 |
Why?
|
| Glucose | 2 | 2016 | 683 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2016 | 9694 | 0.120 |
Why?
|
| Aspirin | 1 | 2017 | 163 | 0.120 |
Why?
|
| Ascites | 1 | 2015 | 57 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 452 | 0.120 |
Why?
|
| Genetic Testing | 1 | 2019 | 550 | 0.120 |
Why?
|
| Lactic Acid | 1 | 2015 | 100 | 0.120 |
Why?
|
| Cell Movement | 1 | 2019 | 801 | 0.120 |
Why?
|
| Survival Rate | 2 | 2016 | 1926 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 199 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 139 | 0.110 |
Why?
|
| Lovastatin | 1 | 2014 | 29 | 0.110 |
Why?
|
| Drug Synergism | 1 | 2014 | 311 | 0.110 |
Why?
|
| Fibronectins | 1 | 2014 | 102 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 470 | 0.110 |
Why?
|
| Likelihood Functions | 1 | 2014 | 252 | 0.110 |
Why?
|
| Mass Screening | 1 | 2018 | 675 | 0.100 |
Why?
|
| Middle Aged | 4 | 2025 | 27045 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 542 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 887 | 0.100 |
Why?
|
| Mitochondria | 1 | 2016 | 595 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2017 | 8730 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 3376 | 0.100 |
Why?
|
| Adult | 4 | 2025 | 27547 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2015 | 464 | 0.090 |
Why?
|
| Estrogen Antagonists | 1 | 2011 | 47 | 0.090 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 85 | 0.090 |
Why?
|
| Anoikis | 1 | 2011 | 7 | 0.090 |
Why?
|
| Coculture Techniques | 3 | 2020 | 171 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 2397 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2011 | 245 | 0.090 |
Why?
|
| Prognosis | 2 | 2016 | 3872 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 80 | 0.090 |
Why?
|
| Anilides | 1 | 2011 | 46 | 0.090 |
Why?
|
| Mice, Transgenic | 2 | 2011 | 1593 | 0.090 |
Why?
|
| Quinolines | 1 | 2011 | 87 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 2013 | 267 | 0.080 |
Why?
|
| Ovary | 1 | 2011 | 263 | 0.080 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 183 | 0.080 |
Why?
|
| fas Receptor | 1 | 2010 | 77 | 0.080 |
Why?
|
| Gonadotropins | 1 | 2009 | 34 | 0.080 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2009 | 49 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 201 | 0.080 |
Why?
|
| Integrases | 1 | 2009 | 64 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 299 | 0.080 |
Why?
|
| Mutation | 2 | 2018 | 4213 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3776 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2009 | 143 | 0.070 |
Why?
|
| Estrogens | 1 | 2009 | 200 | 0.070 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 170 | 0.070 |
Why?
|
| Abortion, Therapeutic | 1 | 2007 | 11 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2014 | 2979 | 0.070 |
Why?
|
| Chicago | 1 | 2012 | 1463 | 0.070 |
Why?
|
| Analgesics | 1 | 2007 | 122 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3514 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 1573 | 0.060 |
Why?
|
| Lipid Metabolism | 2 | 2020 | 213 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 3054 | 0.060 |
Why?
|
| Mice, Knockout | 1 | 2009 | 2098 | 0.060 |
Why?
|
| Diethylstilbestrol | 1 | 2021 | 119 | 0.040 |
Why?
|
| Male | 3 | 2021 | 43929 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2019 | 4474 | 0.040 |
Why?
|
| Succinate-CoA Ligases | 1 | 2019 | 3 | 0.040 |
Why?
|
| Prolyl Hydroxylases | 1 | 2019 | 4 | 0.040 |
Why?
|
| Protein Array Analysis | 1 | 2020 | 52 | 0.040 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2020 | 24 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 61 | 0.040 |
Why?
|
| Risk | 1 | 2021 | 661 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 107 | 0.040 |
Why?
|
| Metabolomics | 1 | 2020 | 95 | 0.040 |
Why?
|
| AC133 Antigen | 1 | 2019 | 10 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 198 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 250 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 63 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2020 | 154 | 0.040 |
Why?
|
| 5-Methylcytosine | 1 | 2020 | 117 | 0.040 |
Why?
|
| Carboplatin | 1 | 2020 | 321 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 523 | 0.040 |
Why?
|
| Proteomics | 1 | 2020 | 246 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 726 | 0.030 |
Why?
|
| Incidence | 1 | 2021 | 1661 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 547 | 0.030 |
Why?
|
| Metabolome | 1 | 2016 | 61 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2016 | 362 | 0.030 |
Why?
|
| Mammography | 1 | 2018 | 471 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2020 | 679 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1194 | 0.030 |
Why?
|
| Integrins | 1 | 2014 | 79 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 87 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 390 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2014 | 431 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 249 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 560 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1938 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 398 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2010 | 23 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2010 | 50 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 260 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 670 | 0.020 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2010 | 51 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2010 | 127 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 515 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1500 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 597 | 0.020 |
Why?
|
| United States | 1 | 2019 | 7367 | 0.020 |
Why?
|
| Obesity | 1 | 2013 | 1014 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 764 | 0.010 |
Why?
|